MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 74 filers reported holding MEREO BIOPHARMA GROUP PLC in Q4 2021. The put-call ratio across all filers is 4.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,241,642 | -6.8% | 962,513 | -4.6% | 0.39% | +6.0% |
| Q2 2023 | $1,331,897 | +71.8% | 1,009,013 | -8.0% | 0.36% | +56.9% |
| Q1 2023 | $775,125 | -5.7% | 1,096,513 | 0.0% | 0.23% | 0.0% |
| Q4 2022 | $822,385 | -12.9% | 1,096,513 | 0.0% | 0.23% | -8.7% |
| Q3 2022 | $944,000 | -23.1% | 1,096,513 | 0.0% | 0.25% | -24.2% |
| Q2 2022 | $1,228,000 | -9.9% | 1,096,513 | -9.9% | 0.34% | -5.6% |
| Q1 2022 | $1,363,000 | -24.4% | 1,216,613 | +8.0% | 0.36% | -21.6% |
| Q4 2021 | $1,803,000 | -33.9% | 1,126,613 | 0.0% | 0.45% | -37.3% |
| Q3 2021 | $2,726,000 | -23.7% | 1,126,613 | 0.0% | 0.72% | -3.2% |
| Q2 2021 | $3,571,000 | -15.2% | 1,126,613 | -9.8% | 0.75% | -25.2% |
| Q1 2021 | $4,211,000 | +76.0% | 1,249,648 | +87.0% | 1.00% | +40.3% |
| Q4 2020 | $2,392,000 | +358.2% | 668,148 | +235.0% | 0.71% | +318.8% |
| Q3 2020 | $522,000 | +122.1% | 199,425 | +159.7% | 0.17% | +150.0% |
| Q2 2020 | $235,000 | – | 76,800 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,048,757 | $6,904,000 | 2.75% |
| Asymmetry Capital Management, L.P. | 1,063,264 | $3,583,000 | 1.85% |
| Endurant Capital Management LP | 1,339,835 | $4,515,000 | 1.18% |
| Altium Capital Management LP | 1,250,000 | $4,213,000 | 1.17% |
| Affinity Asset Advisors, LLC | 900,000 | $3,033,000 | 1.03% |
| DAFNA Capital Management LLC | 1,249,648 | $4,211,000 | 1.00% |
| Boxer Capital, LLC | 6,226,673 | $20,984,000 | 0.71% |
| Delphi Management Partners VIII, L.L.C. | 256,734 | $865,000 | 0.60% |
| Rubric Capital Management LP | 2,914,861 | $9,823,000 | 0.57% |
| Orbimed Advisors | 17,264,763 | $58,183,000 | 0.54% |